Analysis of sunitinib malate, a multi-targeted tyrosine kinase inhibitor: A critical review

被引:6
|
作者
AboulMagd, Asmaa M. [1 ]
Abdelwahab, Nada S. [1 ,2 ]
机构
[1] Nahda Univ NUB, Dept Pharmaceut Chem, Fac Pharm, Bani Suwayf, Egypt
[2] Beni Suef Univ, Dept Pharmaceut Analyt Chem, Fac Pharm, Bani Suwayf, Egypt
关键词
Analytical methods; Sunitinib malate; Multi-targeted tyrosine kinase inhibitor; Therapeutic drug monitoring; N-DESETHYL SUNITINIB; MICELLAR LIQUID-CHROMATOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; LC-MS/MS METHOD; HUMAN PLASMA; ACTIVE METABOLITE; SIMULTANEOUS QUANTIFICATION; CAPILLARY-ELECTROPHORESIS; MULTIKINASE INHIBITOR; VALIDATION;
D O I
10.1016/j.microc.2021.105926
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Sunitinib malate is a multi-targeted tyrosine kinase inhibitor. This work presents a review of characteristics and analytical methods applied for its determination due to the impact of developing effective and reliable analytical methods for quality control analysis, therapeutic drug monitoring, pharmacokinetics, and bioavailability studies. Most of the published methods depended on LC/MS/MS; also ultraviolet spectrophotometric, chemiluminescence, electrochemical, capillary electrophoresis, high-performance thin-layer chromatography, and high-performance liquid chromatography methods were used for estimation of sunitinib. A discussion presented here highlighted the need for developing alternative methods that are money and time saving, need minimum sample pre-treatment steps, consume less toxic solvents, and hence have minimum residue. Also, the literature revealed a deficiency in studying possible drug-drug pharmacokinetic interactions.
引用
下载
收藏
页数:18
相关论文
共 50 条
  • [41] Editorial: Multi-targeted tyrosine kinase inhibitors in the treatment of cancer and neurodegenerative disorders
    Sever, Belgin
    Saso, Luciano
    Tzoneva, Rumiana
    Onnis, Valentina
    Ciftci, Halilibrahim
    FRONTIERS IN CHEMISTRY, 2024, 12
  • [42] A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
    Brian D. Ross
    Youngsoon Jang
    Amanda Welton
    Christopher A. Bonham
    Dilrukshika S. W. Palagama
    Kevin Heist
    Jagadish Boppisetti
    Kasun P. Imaduwage
    Tanner Robison
    Leah R. King
    Edward Z. Zhang
    Cyrus Amirfazli
    Kathryn E. Luker
    Winston Y. Lee
    Gary D. Luker
    Thomas L. Chenevert
    Marcian E. Van Dort
    Nature Communications, 13
  • [43] Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines
    Canter, Daniel
    Kutikov, Alexander
    Golovine, Konstantin
    Makhov, Petr
    Simhan, Jay
    Uzzo, Robert G.
    Kolenko, Vladimir M.
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (04) : 5819 - 5825
  • [44] Thienopyrimidine ureas as novel, potent multi-targeted receptor tyrosine kinase inhibitors
    Dai, YJ
    Guo, Y
    Frey, RR
    Ji, ZQ
    Curtin, ML
    Ahmed, AA
    Albert, DH
    Arnold, L
    Arries, SS
    Barlozzari, T
    Bauch, JL
    Bouska, JJ
    Bousquet, PF
    Cunha, GA
    Glaser, KB
    Guo, J
    Li, JL
    Marcotte, PM
    Marsh, KC
    Moskey, MD
    Pease, LJ
    Stewart, KD
    Stoll, VS
    Tapang, P
    Wishart, N
    Davidsen, SK
    Michaelides, MR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2765 - U2765
  • [45] The novel multi-targeted receptor tyrosine kinase inhibitor MP470 inhibits synovial sarcoma proliferation in vitro
    Combs, D.
    Craniner, L. D.
    Trevor, K. T.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 224 - 225
  • [46] ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
    Jasinghe, Viraj J.
    Xie, Zhigang
    Zhou, Jianbiao
    Khng, Jiaying
    Poon, Lai-Fong
    Senthilnathan, Palaniyandi
    Glaser, Keith B.
    Albert, Daniel H.
    Davidsen, Steven K.
    Chen, Chien-Shing
    JOURNAL OF HEPATOLOGY, 2008, 49 (06) : 985 - 997
  • [47] The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
    Zhang, Junxia
    Zhou, Qiang
    Gao, Ge
    Wang, Yanfen
    Fang, Zhihui
    Li, Guanlin
    Yu, Mengfei
    Kong, Lingfei
    Xing, Ying
    Gao, Xiaoqun
    ONCOTARGETS AND THERAPY, 2014, 7 : 2013 - 2019
  • [48] Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Chu, Tammy F.
    Rupnick, Maria A.
    Kerkela, Risto
    Dallabrida, Susan M.
    Zurakowski, David
    Nguyen, Lisa
    Woulfe, Kathleen
    Pravda, Elke
    Cassiola, Flavia
    Desai, Jayesh
    George, Suzanne
    Morgan, Jeffrey A.
    Harris, David M.
    Ismail, Nesreen S.
    Chen, Jey-Hsin
    Schoen, Frederick J.
    Van den Abbeele, Annick D.
    Demetri, George D.
    Force, Thomas
    Chen, Ming Hui
    LANCET, 2007, 370 (9604): : 2011 - 2019
  • [49] Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
    Qi, Wei-Xiang
    He, Ai-Na
    Shen, Zan
    Yao, Yang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (03) : 348 - 357
  • [50] The multi-targeted kinase inhibitor Sorafenib inhibits Enterovirus 71 IRES activity
    Peng, Y.
    Gao, M.
    Wang, X.
    Zhu, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 453 - 453